Pharmaceutical

ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%

The new OS results came from the Phase III INAVO120 study evaluating an Itovebi triple combination therapy.

May 24, 2025 - 06:00
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
The new OS results came from the Phase III INAVO120 study evaluating an Itovebi triple combination therapy.
Read the original article

Tags:

Previous Article

Genentech to onshore US manufacturing amid rising drug pricing tensions

Next Article

NICE endorses CSL Vifor’s sparsentan for IgA nephropathy in adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone

STAT+: Biden’s SOTU highlights pharma’s biggest politic...

Mar 8, 2024

Anthony Fauci talked Covid in Congress in a nine-hour, closed-door grilling — and that was just day one

Anthony Fauci talked Covid in Congress in a nine-hour, ...

Jan 10, 2024

Will Medicare cover it? Drugs like Aduhelm are challenging its standard

Will Medicare cover it? Drugs like Aduhelm are challeng...

May 25, 2023